Cargando…

Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors

BACKGROUND AND AIM: Some patients with lung cancer can benefit from immunotherapy, but the biomarkers that predict immunotherapy response were not well defined. Baseline characteristic of patients may be the most convenient and effective markers. Therefore, our study was designed to explore the asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiuqiong, Li, Zhaona, Zhou, Jing, Wei, Qianhui, Wang, Xinyue, Jiang, Richeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2022
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760026/ https://www.ncbi.nlm.nih.gov/pubmed/36540802 http://dx.doi.org/10.7717/peerj.14566

Ejemplares similares

A novel pyroptosis-related prognostic signature for lung adenocarcinoma: Identification and multi-angle verification
por: Wang, Xinyue, et al.
Publicado: (2023)

Hypothyroidism induced by immune checkpoint inhibitors combined with antiangiogenic agents is associated with higher body mass index
por: Wang, Xinyue, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
por: Yan, Xuebing, et al.
Publicado: (2023)

Construction and analysis of a novel ferroptosis‐related gene signature predicting prognosis in lung adenocarcinoma
por: Zhou, Jing, et al.
Publicado: (2021)

New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
por: Lin, Xuwen, et al.
Publicado: (2023)

Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study
por: Hu, Fang, et al.
Publicado: (2022)

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
por: Shen, Yi-Luen, et al.
Publicado: (2022)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
por: Davis Puente, Andrea, et al.
Publicado: (2023)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Clinical characteristics and prognostic nomogram analysis of patients with dual primary cancers with first gastric cancer: a retrospective study in China
por: Wang, Bing, et al.
Publicado: (2023)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
por: Sun, Tao, et al.
Publicado: (2023)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors
por: Wang, Li, et al.
Publicado: (2021)

Positive Correlation of Peripheral CD8(+) T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Wu, Kan, et al.
Publicado: (2022)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022)

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer
por: Gao, Chanchan, et al.
Publicado: (2021)

Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients
por: Witteveen, Annemieke, et al.
Publicado: (2015)

Nomogram incorporating log odds of positive lymph nodes improves prognostic prediction for ovarian serous carcinoma: a real-world retrospective cohort study
por: Zhang, Shuming, et al.
Publicado: (2023)

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
por: Matsukane, Ryosuke, et al.
Publicado: (2021)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
por: Liu, Chunxun, et al.
Publicado: (2023)

Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy
por: Zhou, Jiebai, et al.
Publicado: (2023)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes
por: Hu, Beiyuan, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
por: Jiang, Richeng, et al.
Publicado: (2016)

Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and HLA‐I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy
por: Wang, Lin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1kimue2d82rlbhj3ae7v58ojql